Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ananda Basu

Showing results (1-10 of 158) with videos related to

Pageof 16
Sort By:
ACP Journal Club|September 4, 2007
Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapyAnanda Basu
Diabetes Technology & Therapeutics|June 15, 2017
Importance of Artificial Pancreas Standard NomenclatureAnanda Basu
Annals of Internal Medicine|February 17, 2010
ACP Journal Club. Pioglitazone was associated with lower risk for adverse cardiovascular events than rosiglitazone in older patientsAnanda Basu
Evidence-Based Medicine|June 3, 2008
A patient-adjusted insulin algorithm was non-inferior to standard of care for glycaemic control in type 2 diabetesAnanda Basu
Postgraduate Medicine|October 4, 2002
Type 2 diabetes therapy and liver damage: the debate continuesFarhad Zangeneh, Ananda Basu
Diabetes Technology & Therapeutics|December 1, 2015
Insulin:Carbohydrate Ratio--Part of the StoryAnanda Basu, Rita Basu
Diabetes Technology & Therapeutics|July 2, 2015
Technology Use for Problem Solving in Adolescent Type 1 DiabetesLing Hinshaw, Ananda Basu
Evidence-Based Medicine|January 11, 2007
Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in type 2 diabetes mellitusYogish C Kudva, Ananda Basu
ACP Journal Club|November 4, 2006
Adjunctive inhaled insulin before meals improved glycemic control more than adjunctive metformin in type 2 diabetes mellitusYogish C Kudva, Ananda Basu
Lancet (London, England)|March 15, 2011
Ultra-long-acting insulins for a lifestyle-related pandemicYogish C Kudva, Ananda Basu
Pageof 16

Showing results (1-10 of 158) with videos related to

Sort By:
Pageof 16
ACP Journal Club|September 4, 2007
Vildagliptin was effective as add-on therapy in type 2 diabetes inadequately controlled with metformin monotherapyAnanda Basu
Diabetes Technology & Therapeutics|June 15, 2017
Importance of Artificial Pancreas Standard NomenclatureAnanda Basu
Annals of Internal Medicine|February 17, 2010
ACP Journal Club. Pioglitazone was associated with lower risk for adverse cardiovascular events than rosiglitazone in older patientsAnanda Basu
Evidence-Based Medicine|June 3, 2008
A patient-adjusted insulin algorithm was non-inferior to standard of care for glycaemic control in type 2 diabetesAnanda Basu
Postgraduate Medicine|October 4, 2002
Type 2 diabetes therapy and liver damage: the debate continuesFarhad Zangeneh, Ananda Basu
Diabetes Technology & Therapeutics|December 1, 2015
Insulin:Carbohydrate Ratio--Part of the StoryAnanda Basu, Rita Basu
Diabetes Technology & Therapeutics|July 2, 2015
Technology Use for Problem Solving in Adolescent Type 1 DiabetesLing Hinshaw, Ananda Basu
Evidence-Based Medicine|January 11, 2007
Adjunctive inhaled insulin before meals improved glycaemic control more than adjunctive metformin in type 2 diabetes mellitusYogish C Kudva, Ananda Basu
ACP Journal Club|November 4, 2006
Adjunctive inhaled insulin before meals improved glycemic control more than adjunctive metformin in type 2 diabetes mellitusYogish C Kudva, Ananda Basu
Lancet (London, England)|March 15, 2011
Ultra-long-acting insulins for a lifestyle-related pandemicYogish C Kudva, Ananda Basu
Pageof 16